Takeda Pharmaceutical Co. Ltd. is providing substantial launch support to a new US venture focusing on novel regenerative approaches to serious liver diseases, in a move the company says aligns with its strategic focus areas.
Takeda Alliance Boosts Liver Disease Venture Ambys’s $140m Launch
Takeda is investing in newly launched serious liver disease company Ambys Medicines to support the advancement of the US venture’s platform and pipeline, in line with its core strategic therapeutic priorities.